Rohto Pharmaceutical plans clinical trials in Hong Kong as first Japan partner
Japanese drug maker Rohto Pharmaceutical announced plans to conduct clinical trials in Hong Kong, becoming the first company from Japan to partner with the Office for Attracting Strategic Enterprises.
Strategic partnership announcement details
Rohto Pharmaceutical joins a batch of 18 firms recruited by OASES under a flagship investment initiative. The firm is known for its over-the-counter eye care and skincare products before expanding into clinical research.
Reasons for choosing the city
Chairman Kunio Yamada stated that Hong Kong's top university research capabilities attracted the firm to expand in the region. He also cited cross-border data exchanges and access to mainland China's large market as key draws for the decision.
Government unit recruitment efforts
The Office for Attracting Strategic Enterprises operates under the Financial Secretary's Office to attract companies of strategic importance. This specific initiative aims to bring Japanese firms like Rohto into the local ecosystem through government partnerships.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.